English
| dc.contributor.author | Gök, S | |
| dc.contributor.author | Önal, A | |
| dc.contributor.author | Çinar, MG | |
| dc.contributor.author | Evinç, A | |
| dc.date.accessioned | 2024-07-18T11:58:05Z | |
| dc.date.available | 2024-07-18T11:58:05Z | |
| dc.description.abstract | ELSEVIER SCIENCE BV | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/7264 | |
| dc.language.iso | Article | |
| dc.publisher | 0014-2999 | |
| dc.subject | The effect of a leukotriene D-4 receptor antagonist, (3-(3-(2-(7-chloro-2-quinolinyl)ethenyl) amino-3-oxo plopyl)thio)methyl)thio) propanoic acid (L-660,711; MK-571), was investigated on nociceptive responses in mice using three different assays: acetic-acid-induced abdominal constrictions, formalin response and tail-flick test. MK-571 (8-32 mg/kg, i.v.) produced dose-dependent protection against acetic-acid-induced abdominal constriction (ED50 = 30 mg/kg). The compound (10-80 mg/kg, i.p.) was also effective, in a dose-dependent manner, on the second phase of the formalin response (ED50 = 26 mg/kg). However, it had no effect on the first phase of the formalin response and in the tail-flick test. Naloxone (1 mg/kg, i.v.), an opioid antagonist, almost completely blocked the antinociceptive effect of MK-571 in both acetic-acid-induced abdominal constriction and the second phase of the formalin test. These results provide evidence for an antinociceptive action of MK-571 at peripheral sites and suggest that opioid mechanisms are involved. (C) 1999 Elsevier Science B.V. All rights reserved. | |
| dc.title | English | |
| dc.type | FORMALIN TEST | |
| dc.type | POLYMORPHONUCLEAR LEUKOCYTES | |
| dc.type | INTRAPERITONEAL INJECTION | |
| dc.type | HYPERALGESIA | |
| dc.type | INFLAMMATION | |
| dc.type | RAT | |
| dc.type | PHARMACOLOGY | |
| dc.type | MEDIATORS | |
| dc.type | NALOXONE | |
| dc.type | AGONISTS |